Clinical Trials Logo

Clinical Trial Summary

The objective of the study is to determine if a weekly dose of 17 hydroxyprogesterone caproate (17P, Makena®) given to women with preterm rupture of the membranes will:

1. increase the probability of continuing the pregnancy until a favorable gestational age.

2. increase the interval between randomization and delivery.

3. decrease neonatal morbidity.


Clinical Trial Description

Preterm rupture of the membranes (PROM) is the leading identifiable cause of prematurity and accounts for about one-third of all preterm deliveries and 18-20% of perinatal deaths in the USA. When PROM occurs at very early gestational ages, the clinician must make a decision whether to attempt to prolong the pregnancy or whether to recommend prompt delivery. Both approaches carry substantial risk. The strategy of continuing the pregnancy is commonly called "expectant management." During expectant management, gestational age steadily increases, and the balance naturally shifts toward favoring delivery. Once the gestational age reaches 34 weeks, the risk of lethal or permanent sequelae of prematurity or minimal, so most clinicians agree that delivery is warranted. Despite an attempt at expectant management, the majority of patients with PROM will be delivered within the first week or so. Unfortunately, no intervention other than antibiotic prophylaxis or corticosteroids have been shown to prolong latency or reduce neonatal morbidity after PROM. Recent evidence suggests that prophylactic administration of progesterone medications may reduce the risk of preterm delivery in women with certain risk factors, notably those with a history of a prior preterm delivery and those with a shortened cervix discovered by ultrasound examination. Clearly, women with PROM are at very high risk of preterm delivery, so there is a pressing need to study whether 17 hydroxyprogesterone caproate (17P) is effective after PROM. Progesterone might be beneficial after PROM both because it tends to promote uterine quiescence by suppressing the formation of myometrial gap junctions and because it has anti-inflammatory properties, suppressing the production of inflammatory cytokines and thereby inhibiting cervical ripening. Inflammation is a major pathway leading to preterm labor, cervical dilation & preterm delivery. 17P would seem to be like an ideal candidate for prolongation of pregnancy after PROM.

This is a double-blinded, placebo-controlled, multicenter, randomized clinical trial of 17P versus placebo. The primary outcome measure will be the percentage of each group reaching either a gestational age of 34w0d or documentation of fetal lung maturity at 32w0d to 33w6d. Secondary outcomes will include the latency period for each group and the percentage of newborns in each group who have major neonatal morbidity or death. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01119963
Study type Interventional
Source Mednax Center for Research, Education, Quality and Safety
Contact
Status Completed
Phase Phase 2/Phase 3
Start date October 2011
Completion date October 2014

See also
  Status Clinical Trial Phase
Completed NCT03304782 - Fitbit Activity Tracker to Predict Risk of Preterm Birth
Recruiting NCT02420743 - Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
Completed NCT01665378 - Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes N/A
Completed NCT00141908 - Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate Phase 2
Recruiting NCT05278130 - Serial Screening and Treatment of Bacterial Vaginosis Trial N/A
Terminated NCT03596125 - Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP) Phase 2/Phase 3
Recruiting NCT03123926 - Spontaneous Preterm Birth Marker Test N/A
Completed NCT00201643 - A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Phase 4
Completed NCT01353807 - Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health N/A
Terminated NCT02545127 - Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely Phase 2
Completed NCT02371356 - Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
Active, not recruiting NCT01009723 - Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers N/A
Completed NCT00883324 - Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum N/A
Completed NCT00615550 - PREGNANT Short Cervix Trial Phase 3
Completed NCT02694679 - Randomized Controlled Trial of Social Network Targeting in Honduras N/A
Completed NCT01031017 - Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies Phase 4
Completed NCT00331695 - Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Phase 4
Completed NCT00329914 - Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies? Phase 2
Completed NCT01818518 - Neonatal Outcome by Reason for Delivery
Completed NCT04637880 - 25- Hydroxyvitamin D Levels in Pregnancy and Effects on Pregnancy Related Disorders